New Nano-Carrier Tested for Potential Treatment of Glioblastomas Written by AZoNanoFeb 24 2021 Glioblastoma multiforme, the most common and aggressive form of primary brain tumor, has a survival rate of just five years. It is particularly challenging to treat, with existing therapies depending on chemotherapy, radiation, surgery, and their combinations. Sheereen Majd, assistant professor of biomedical engineering, is the first to report on targeted delivery of Dp44mT to malignant tumors. Image Credit: University of Houston. Two of the major challenges in the treatment of gl...